Relief For UniQure Hemophilia Program Sends Ball To FTC’s Court
Good News For Gene Therapy Continues As FDA Also Removes Hold On Voyager’s Huntington’s Trial
While anticipated, the removal of the hold on uniQure’s hemophilia B program removes significant overhang, as the focus shifts to an anticipated FTC antitrust clearance of its CSL Behring deal.
